# Coherus Biosciences Inc. (CHRS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $159M  
**Price:** $1.36 (-4.23%)

> Coherus Biosciences Inc. is a commercial-stage biopharmaceutical company focused on oncology therapeutics. It develops and commercializes innovative treatments, including the FDA-approved next-generation PD-1 inhibitor LOQTORZI (toripalimab-tpzi), approved for nasopharyngeal carcinoma and other cancers. The company also offers UDENYCA, a biosimilar referencing Neulasta for supportive care in oncology, and YUSIMRY, a Humira biosimilar. Its pipeline features mid-stage clinical candidates like CHS-114, a selective anti-CCR8 antibody targeting regulatory T cells in solid tumors such as head and neck, gastric, esophageal, and colorectal cancers, and casdozokitug, an IL-27 antagonist for liver, lung, and other advanced solid tumors. Coherus Biosciences Inc. emphasizes proprietary combinations and synergies with industry partners to advance immuno-oncology treatments. Founded in 2010 and headquartered in Redwood City, California, it operates in the biotechnology sector, generating revenue primarily from the United States through its diversified portfolio of approved products.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $42M | $28M | -$181M | $168M | — |
| 2024 | $26M | $18M | -$200M | $29M | — |
| 2023 | $257M | $98M | -$203M | -$238M | — |
| 2022 | $211M | $141M | -$257M | -$292M | — |
| 2021 | $327M | $269M | -$264M | -$287M | — |
| 2020 | $476M | $438M | $156M | $132M | — |
| 2019 | $356M | $339M | $108M | $90M | — |
| 2018 | — | — | -$204M | -$209M | — |
| 2017 | $2M | — | -$232M | -$238M | — |
| 2016 | $189M | — | -$116M | -$127M | — |
| 2015 | $30M | — | -$219M | -$223M | — |
| 2014 | $31M | — | -$65M | -$87M | — |
| 2013 | $3M | — | -$36M | -$54M | — |
| 2012 | $2M | — | -$39M | -$33M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $258M | $197M | $61M | $89M | — |
| 2024 | $449M | $581M | -$132M | $126M | — |
| 2023 | $630M | $823M | -$193M | $103M | — |
| 2022 | $481M | $618M | -$137M | $64M | — |
| 2021 | $679M | $582M | $98M | $417M | — |
| 2020 | $842M | $561M | $281M | $541M | — |
| 2019 | $409M | $304M | $105M | $178M | $74M |
| 2018 | $99M | $138M | -$39M | $72M | — |
| 2017 | $163M | $132M | $31M | $127M | — |
| 2016 | $178M | $159M | $21M | $125M | — |
| 2015 | $212M | $219M | -$6M | $158M | — |
| 2014 | $187M | $120M | $67M | $150M | — |
| 2013 | $47M | $90M | -$97M | $40M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$139M | — | — |
| 2024 | -$20M | — | — |
| 2023 | -$175M | $286,000 | -$175M |
| 2022 | -$241M | $2M | -$243M |
| 2021 | -$37M | $1M | -$39M |
| 2020 | $154M | $7M | $147M |
| 2019 | $28M | $2M | $27M |
| 2018 | -$159M | $789,000 | -$160M |
| 2017 | -$200M | $5M | -$205M |
| 2016 | -$253M | $7M | -$259M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CHRS)